Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the...

Related Keywords

New York ,United States ,Ireland ,Dublin ,American ,Johnh Krystal ,Kristin Bhavnani ,Andrean Flynn ,Rob Iannone ,Robertl Mcneil Jr ,American Psychiatric Association ,Glaxosmithkline ,Commission File No ,Ment Health Clin ,Jazz Pharmaceuticals ,National Epidemiologic Survey On Alcohol ,Nasdaq ,Pfizer Inc ,Research Triangle Park ,Yale University ,National Center ,Drug Administration ,American Psychological Association ,Head Of Global Corporate Communications ,Jazz Pharmaceuticals Acquires Springworks Therapeutic ,Inhibitor Program ,Exchange Commission ,Fast Track ,Statistical Manual ,Mental Disorders ,Clinical Global Impressions Severity ,Patient Global Impression ,Springworks Therapeutics ,Jazz Pharmaceutical ,Commission File ,Jazz Pharmaceutical Quarterly Report ,Global Corporate Communications ,Psychiatric Association ,American Psychiatric Publishing ,National Epidemiologic Survey ,Soc Psychiatry Psychiatr ,Ment Health ,Post Traumatic Stress ,Accessed December ,Jazz Pharmaceuticals Plc ,